About: Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Creator	Singh, Aditi Halmos, Balazs Cheng, Haiying Goel, Sanjay Perez-Soler, Roman Rajdev, Lakshmi Shum, Elaine
source	PMC
abstract	Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., EGFR/ALK for non-small cell lung cancer (NSCLC) and extended-RAS for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.
has issue date	2020-05-04(xsd:dateTime)
bibo:doi	10.3390/cancers12051156
bibo:pmid	32375398
has license	cc-by
sha1sum (hex)	15336bdeec5e4eebc7c4d2ef8ca85dc4c8eeaf05
schema:url	https://doi.org/10.3390/cancers12051156
resource representing a document's title	Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
has PubMed Central identifier	PMC7281757
has PubMed identifier	32375398
schema:publication	Cancers (Basel)
resource representing a document's body	covid:15336bdeec5e4eebc7c4d2ef8ca85dc4c8eeaf05#body_text
is schema:about of	named entity 'Food' named entity 'testing' named entity 'conducted' named entity 'management' named entity 'alteration' named entity 'Results' named entity 'off-label' named entity 'CONCLUSION' named entity 'CGP' named entity 'NEXT-GENERATION SEQUENCING' named entity 'CANCER' named entity 'UNKNOWN' named entity 'RESULTS' named entity 'EXTENDED' named entity 'Conclusion' named entity 'modest' named entity 'clinical trial' named entity 'majority' named entity 'national' named entity '2017' named entity 'alterations' named entity 'genomic' named entity 'remains' named entity 'clinical trial' named entity 'national guidelines' named entity 'colorectal cancer' named entity 'NCI' named entity 'Food and Drug Administration' named entity 'retrospective study' named entity 'RAS' named entity 'NSCLC' named entity 'NSCLC' named entity '95%' named entity 'Treatment' named entity 'treated' named entity 'molecular profiling' named entity 'gene' named entity 'clinical practice' named entity 'HER2' named entity 'Centers for Medicare and Medicaid Services' named entity 'NSCLC' named entity 'tumor' named entity 'clinical trials' named entity 'Kinase' named entity 'targeted therapy' named entity 'WGS' named entity 'NGS' named entity 'targeted therapy' named entity 'histology' named entity 'clinical trials' named entity 'pancreatic tumor' named entity 'genotyping' named entity 'ALK' named entity 'sarcoma' named entity 'IRB' named entity 'oncogene' named entity 'Medicaid' named entity 'plasma' named entity 'FDA' named entity 'TRK' named entity 'NTRK' named entity 'Anaplastic Lymphoma Kinase' named entity 'genetic sequencing' named entity 'mutation' named entity 'EGFR' named entity 'colorectal cancer' named entity 'oncogenic' named entity 'Tumor' named entity 'metastatic' named entity 'standard of care' named entity 'gene' named entity 'solid tumors' named entity 'Targeted therapy' named entity 'private insurance' named entity '1/4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software